Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus

Glycemic effect of incretin therapeutics as monotherapy. HbA_1c = hemoglobin A_1c; LAR = long-acting release. *Not currently approved for use in the United States; ^†not currently approved for use in the United States or European Union; ^‡significant vs. baseline; ^§significant vs. comparator drug; ^∥significant vs. placebo; ^¶not currently approved as monotherapy. (Adapted from Diabetes Care, Clin Ther,¹⁸ Lancet,¹⁹ European Association for the Study of Diabetes,²⁰ Diabetologia,²² and Diabet Med.²³)

Glycemic effect of incretin therapeutics combined with metformin. HbA_1c = hemoglobin A_1c. *Not currently approved for use in the United States or European Union; ^†significant vs. placebo; ^‡not currently approved for use in the United States. (Adapted from Diabetes Care.)

Glycemic effect of incretin therapeutics combined with a sulfonylurea drug. HbA_1c = hemoglobin A_1c. *Not currently approved for use in the United States or European Union; ^†adjusted value; ^‡significant vs. placebo; ^§significant between-group differences vs. placebo; ^∥not currently approved for use in United States. (Adapted from Diabet Med,²⁹ Diabetes Care,³⁰ and Diabetes Obes Metab.)

Glycemic effect of incretin therapeutics combined with a thiazolidinedione. HbA_1c = hemoglobin A_1c. *Not currently approved for use in the United States; ^†significance in the intent-to-treat sample; ^‡significant vs. baseline; ^§significant vs. placebo. (Adapted from Ann Intern Med,³³ Clin Ther,³⁴ and Diabetes Obes Metab.)

Glycemic effect of incretin therapeutics combined with 2 oral agents. HbA_1c = hemoglobin A_1c; met = metformin; SU = sulfonylurea; TZD = thiazolidinedione. *Significance adjusted vs. placebo; ^†significant vs. baseline; ^‡not currently approved for use in the United States or European Union. (Adapted from Diabetes Care, Diabetologia,³⁸ and Ann Intern Med.)